古塞奇尤单抗治疗中重度斑块状银屑病23例临床观察  

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis

作　　者：夏丽晔 范琳婵 王为平[1] 尚智伟[1] XIA Liye;FAN Linchan;WANG Weiping;SHANG Zhiwei(Clinical Medical College of He′nan University of Science and Technology,First Affiliated Hospital of He′nan University of Science and Technology,Luoyang 471003,China)

机构地区：[1]河南科技大学临床医学院河南科技大学第一附属医院,河南洛阳471003

出　　处：《皮肤性病诊疗学杂志》2024年第3期175-179,共5页Journal of Diagnosis and Therapy on Dermato-venereology

摘　　要：目的观察古塞奇尤单抗注射液治疗中重度斑块状银屑病的短期临床疗效及安全性。方法纳入23例中重度斑块状银屑病患者,分别于第0、4周皮下注射古塞奇尤单抗注射液,100 mg/次,随后每8周1次,于第4、12周时评价患者银屑病皮损面积和严重程度指数(PASI),记录药物不良反应。结果23例患者均在第0、4、12周接受了3次皮下注射古塞奇尤单抗的治疗,无1例退出。12周时,23例(100%)患者均达到PASI 75以上,19例(82.61%)达到PASI 90,10例(43.48%)达到PASI 100。23例患者均未发生严重不良反应。结论古塞奇尤单抗治疗中重度斑块状银屑病起效快速,疗效显著,安全性高,为患者提供了新的治疗药物选择。Objective To observe the clinical efficacy and safety of guselkumab injection in the treatment of moderate to severe plaque psoriasis.Methods Twenty three patients with moderate to severe plaque psoriasis were treated with subcutaneous injection of guselkumab at a dose of 100 mg at weeks 0 and 4,followed by once every 8 weeks.The psoriasis lesion area and severity index(PASI)were evaluated at weeks 4 and 12,and adverse reactions were recorded.Results All 23 patients received treatment at least 3 times(0,4,12 weeks).At week 12,23 patients(100%)achieved PASI 75 or above,including PASI 90 in 19 patients(82.61%)and PASI 100 in 10 patients(43.48%).No serious adverse reactions were observed.Conclusions Guselkumab is safe and effective for moderate to severe plaque psoriasis,and can rapidly improve skin lesions.It provides a new treatment option for patients with moderate to severe plaque psoriasis.

关 键 词：银屑病 生物制剂 白介素23 古塞奇尤单抗 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]